E-resources
Peer reviewed
Open access
-
Da Cruz Paula, Arnaud; DeLair, Deborah F.; Ferrando, Lorenzo; Fix, Daniel J.; Soslow, Robert A.; Park, Kay J.; Chiang, Sarah; Reis-Filho, Jorge S.; Zehir, Ahmet; Donoghue, Mark T.A.; Wu, Michelle; Brown, David N.; Murali, Rajmohan; Friedman, Claire F.; Zamarin, Dmitriy; Makker, Vicky; Mueller, Jennifer J.; Leitao, Mario M.; Abu-Rustum, Nadeem R.; Aghajanian, Carol; Weigelt, Britta
Gynecologic oncology, 05/2021, Volume: 161, Issue: 2Journal Article
To characterize and compare the molecular subtypes and profiles of prospectively-accrued newly-diagnosed early- and advanced-stage endometrial cancers (ECs). EC patients consented to an IRB-approved protocol of massively parallel sequencing of 410–468 cancer-related genes; 175 ECs of 7 histologic types (n = 135 FIGO stages I/II, n = 40 FIGO stages III/IV) were included. Previously reported sequencing data from 99 additional advanced-stage ECs were retrieved for comparisons. Irrespective of histologic type, all 175 ECs could be stratified into the molecular subtypes, with 75 (43%) being of p53 wild-type, 49 (28%) MMR-deficient, 39 (22%) p53 abnormal and 12 (7%) of POLE molecular subtypes. Subtype distribution, mutational and copy number profiles varied according to histologic type. In endometrioid ECs, genetic alterations varied according to histologic grade. Potential therapeutic targets, including high tumor mutational burden, ERBB2 amplification and PIK3CA hotspot mutations, were found across histologic types in 63% (n = 110) of all ECs. Compared to their early-stage counterparts, advanced-stage endometrioid ECs had a significantly higher fraction of genome altered (median 0.1% vs 12%, p < 0.001) and ARID1B mutations (0% vs 11%, p = 0.01), and advanced-stage serous ECs harbored more frequent ERBB2 amplification (18% vs 8%, p > 0.05) and PIK3CA mutations (46% vs 27%, p > 0.05). Whole-genome doubling was found in advanced- but not early-stage carcinosarcomas and clear cell carcinomas. Our findings demonstrate the molecular heterogeneity within and across histologic types of EC and the increased genomic complexity of advanced-stage ECs. Molecular subtypes are present across EC histologic types and may help stratify EC patients for prognostic and therapeutic purposes. •Molecular subtype distribution varies according to histologic types of EC.•Advanced-stage endometrioid ECs show increased genomic instability.•ERBB2 amplification is more common in advanced- than early-stage serous ECs.•Whole-genome doubling is found in advanced- but not early-stage carcinosarcomas and clear cell carcinomas.•Potential therapeutic targets were identified in >60% of ECs.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.